Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al
Mol Psychiatry
.
2022 Apr;27(4):1860-1862.
doi: 10.1038/s41380-022-01447-4.
Epub 2022 Feb 17.
Authors
Guang Chen
1
,
Geert Mannens
2
,
Marlies De Boeck
3
,
Ella J Daly
4
,
Carla M Canuso
5
,
Greet Teuns
3
,
Husseini Manji
6
,
Wayne C Drevets
7
Affiliations
1
Neuroscience, Janssen Research & Development, LLC, San Diego, CA, USA.
[email protected]
.
2
Drug Metabolism and Pharmacokinetics, Janssen Research & Development, Beerse, Belgium.
3
Non-Clinical Safety, Janssen Research & Development, Beerse, Belgium.
4
Neuroscience Medical Affairs, Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
5
Neuroscience Clinical Development, Janssen Research & Development, LLC, Titusville, NJ, USA.
6
Science for Minds, Johnson & Johnson, New Brunswick, NJ, USA.
7
Neuroscience, Janssen Research & Development, LLC, San Diego, CA, USA.
[email protected]
.
PMID:
35177823
PMCID:
PMC9126803
DOI:
10.1038/s41380-022-01447-4
No abstract available
Publication types
Letter
Comment
MeSH terms
Ketamine* / pharmacology
Stereoisomerism
Substances
Ketamine